Unambiguous Detection of Multiple TP53 Gene Mutations in AAN-Associated Urothelial Cancer in Belgium Using Laser Capture Microdissection

The Epidemiology, Diagnosis, and Management of Aristolochic Acid Nephropathy

(2013) M. Refik Gökmen et al.   ANNALS OF INTERNAL MEDICINE

Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: Clinical characteristics and outcomes

(2013) Chung-Hsin Chen et al.   INTERNATIONAL JOURNAL OF CANCER

Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease

(2012) Arthur P. Grollman   ENVIRONMENTAL AND MOLECULAR MUTAGENESIS

Aristolochic acid-associated urothelial cancer in Taiwan

(2012) C.-H. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TP53 Mutational signature for aristolochic acid: an environmental carcinogen

(2011) Masaaki Moriya et al.   INTERNATIONAL JOURNAL OF CANCER

Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid

(2011) Bojan Jelaković et al.   KIDNEY INTERNATIONAL

Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing

(2010) Ahmad Besaratinia et al.   FASEB JOURNAL

Paraffin-embedded tissue is less accurate than frozen section analysis for determining VHL mutational status in sporadic renal cell carcinoma

(2010) Grégory Verhoest et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features

(2009) Kurt B. Hodges et al.   HUMAN PATHOLOGY

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

(2009) M. Olivier et al.   Cold Spring Harbor Perspectives in Biology

TP53mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours

(2008) Tatiana Nedelko et al.   INTERNATIONAL JOURNAL OF CANCER